| 0.866 -0.034 (-3.77%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.19 | 1-year : | 1.39 |
| Resists | First : | 1.01 | Second : | 1.19 |
| Pivot price | 0.74  |
|||
| Supports | First : | 0.74 | Second : | 0.56 |
| MAs | MA(5) : | 0.88 |
MA(20) : | 0.74 |
| MA(100) : | 0.87 |
MA(250) : | 1.06  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 67.7 |
D(3) : | 69.8 |
| RSI | RSI(14): 56.6 |
|||
| 52-week | High : | 2.08 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VNRX ] has closed below upper band by 25.2%. Bollinger Bands are 58.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.91 - 0.92 | 0.92 - 0.92 |
| Low: | 0.83 - 0.83 | 0.83 - 0.84 |
| Close: | 0.86 - 0.87 | 0.87 - 0.87 |
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
Fri, 26 Apr 2024
VolitionRX Announces Board Reshuffle and Bylaws Amendment - TipRanks.com - TipRanks
Thu, 18 Apr 2024
VolitionRx (NYSE:VNRX) Receives New Coverage from Analysts at StockNews.com - MarketBeat
Mon, 08 Apr 2024
VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key ... - Yahoo Finance
Wed, 27 Mar 2024
Earnings call: VolitionRx reports robust revenue growth, eyes breakeven - Investing.com
Wed, 27 Mar 2024
VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript - Yahoo Finance
Tue, 26 Mar 2024
Volitionrx Ltd Up 10.53% To $0.80 After Earnings Meet - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 5.949e+007 (%) |
| Held by Institutions | 24.6 (%) |
| Shares Short | 794 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.415e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 237.5 % |
| Return on Equity (ttm) | -106.5 % |
| Qtrly Rev. Growth | 651040 % |
| Gross Profit (p.s.) | 251.55 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 190304 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -46.48 |
| Dividend | 0 |
| Forward Dividend | 704050 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|